Chronic Kidney Disease

 

Allopurinol Doesn’t Slow Kidney Disease

October 23, 2020

The gout treatment allopurinol doesn't appear to slow the progression of chronic kidney disease in patients with moderate to severe loss of kidney function, shows a study presented yesterday at the American Society of Nephrology Kidney Week annual meeting.

Dapagliflozin Earns Breakthrough Therapy Designation for Chronic Kidney Disease

October 02, 2020

Dapagliflozin (Farxiga, AstraZeneca) has been granted breakthrough therapy designation by the U.S. Food and Drug Administration for patients with chronic kidney disease with and without type 2 diabetes. It is currently approved as a treatment to improve glycemic control in adults with type 2 diabetes.

Kidney Deterioration Not Aggravated by Allopurinol

November 21, 2016

Allopurinol is not associated with an increased risk of renal function deterioration, a study presented at ACR 2016 shows.

Kidney Deterioration Not Aggravated by Allopurinol

November 21, 2016

Allopurinol is not associated with an increased risk of renal function deterioration, a study presented at ACR 2016 shows.